Gastric Cancer Market Insights, Epidemiology, and Market Forecast 2030
(Albany, US) DelveInsight ha s launched a new report Gastric Cancer Market
DelveInsight’s Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Gastric Cancer, historical and forecasted epidemiology as well as the Gastric Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Gastric Cancer market report provides current treatment practices, emerging drugs, Gastric Cancer market share of the individual therapies, current and forecasted Gastric Cancer market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Gastric Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Click Here For Free Sample Page:- https://www.delveinsight.com/sample-request/gastric-cancer-market
Gastric Cancer Market Outlook
The Gastric Cancer market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Gastric Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Gastric Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Gastric Cancer market in 7MM is expected to change in the study period 2017-2030
KEY FACT FROM THE REPORT
- Approximately 0.9% of men and women are diagnosed with Gastric Cancer at some point during their lifetime, based on 2014-2016 data.
- The number of new cases of Gastric Cancer and deaths was 7.4/100,000 men and women/year, and 3.1/100,000 men and women/year, respectively. These rates are age-adjusted and based on cases and deaths in 2012–2016.
- In 2016, an estimated 113,054 people were living with Gastric Cancer in the United States.
MAJOR KEY PLAYERS OF THE REPORT
- Innovent Biologics
- RemeGen Co.
- Surface Oncology
NAME OF DRUGS COVERED IN THE REPORT
- IBI308
- RC48
- SRF617
Table of content
1. Key Insights
2. Executive Summary of Gastric Cancer
3. Competitive Intelligence Analysis for Gastric Cancer
4. Gastric Cancer Market Overview at a Glance
4.1. Gastric Cancer Market Share (%) Distribution in 2017
4.2. Gastric Cancer Total Market Share (%) Distribution in 2030
5. Gastric Cancer: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Gastric Cancer Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Gastric Cancer Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Gastric Cancer Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Gastric Cancer Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Gastric Cancer Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Gastric Cancer Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Gastric Cancer Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Gastric Cancer Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Gastric Cancer Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Gastric Cancer Treatment and Management
8.2. Gastric Cancer Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Gastric Cancer Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Gastric Cancer: Seven Major Market Analysis
13.1. Key Findings
13.2. Gastric Cancer Market Size in 7MM
13.3. Gastric Cancer Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Gastric Cancer Total Market Size in the United States
15.1.2. Gastric Cancer Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Gastric Cancer Total Market Size in Germany
15.3.2. Gastric Cancer Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Gastric Cancer Total Market Size in France
15.4.2. Gastric Cancer Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Gastric Cancer Total Market Size in Italy
15.5.2. Gastric Cancer Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Gastric Cancer Total Market Size in Spain
15.6.2. Gastric Cancer Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Gastric Cancer Total Market Size in the United Kingdom
15.7.2. Gastric Cancer Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Gastric Cancer Total Market Size in Japan
15.8.3. Gastric Cancer Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Gastric Cancer
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
ABOUT DELVEINSIGHT
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.
CONTACT US:
Shruti Thakur
[email protected]
+91-9650213330
DelveInsight